Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma (HSP70)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct sequencing. The clinical relevance of patients will be compared in those with polymorphism and those without.
| Condition | Intervention |
|---|---|
|
Hepatocellular Carcinoma |
Genetic: Polymorphisms of HSP70 and TNF promoter |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma |
- Clinical relevance [ Time Frame: year ] [ Designated as safety issue: No ]
- Clinical relevance [ Time Frame: year ] [ Designated as safety issue: No ]
| Enrollment: | 600 |
| Study Start Date: | January 2006 |
| Study Completion Date: | June 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: HSP70 and TNF polymorphisms |
Genetic: Polymorphisms of HSP70 and TNF promoter
To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
Other Names:
|
Detailed Description:
Heat shock protein 70 (HSP 70) may be involved in various aspects of immune system including infection, autoimmunity, and tumor immunity. The relationship between HSP70 expression, disease activity and cancer prognosis varied according to type of cancer. The overexpression of HSP70 by tumor cells contributes to tumor behavior. HSP70 is present in normal and abnormal hepatocytes, and was reported to be over-expressed in both hepatoma cell lines and human hepatocellular carcinoma (HCC) tissue. Recent study indicated that HSP70 is a molecular marker during early hepatocarcinogenesis. It is also involved in anti-tumor immunity in HCC.We also investigate the polymorphism of tumor necrosis factor-alpha promoter, and correlated to clinical relevance.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- History proven HCC patients
Exclusion Criteria:
- No-definite diagnosed patients
Contacts and Locations| Taiwan | |
| Kaohsiung Medical University | |
| Kaohsiung, Kaohsiun, Taiwan, 807 | |
| Kaohsiung Medical University | |
| Kaohsiung, Taiwan, 807 | |
| Principal Investigator: | Jung-Fa Tsai, M.D., Ph.D. | Professor of Medicine |
More Information
No publications provided
| Responsible Party: | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT00769535 History of Changes |
| Other Study ID Numbers: | KMUH-IRB-930047 |
| Study First Received: | February 26, 2008 |
| Last Updated: | April 26, 2013 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
|
heat shock protein70 tumor necrosis factor-alpha promoter polymorphism |
Additional relevant MeSH terms:
|
Carcinoma Shock Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Pathologic Processes |
Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |
ClinicalTrials.gov processed this record on May 23, 2013